Skip to main content

BioGaia (SE)

BioGaia AB is a Swedish healthcare company engaged in the development and commercialization of probiotic products. The company operates primarily through two business segments: Pediatrics and Adults. Its product portfolio is based on proprietary strains of Limosilactobacillus reuteri bacteria, packaged as drops, chewable tablets, capsules, and lozenges. Primary revenue drivers are product sales of finished probiotic supplements alongside component supply and royalty fees from distribution partners. BioGaia holds a leading global market position in pediatric probiotic drops and gut health solutions. The company is headquartered in Stockholm, Sweden, and its shares are listed on Nasdaq Stockholm.

32 of the funds FundTelligence covers report a position in BioGaia (SE).

Sector
Health Care
Country
Sweden
Funds holding it
32

Funds holding BioGaia (SE)

Showing the 8 largest of 32 funds holding it.

Loading...